Solid Biosciences Inc (OQ:SLDB)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 500 RUTHERFORD AVENUE, 3RD FLOOR
CHARLESTOWN MA 02129
Tel: N/A
Website: https://www.solidbio.com
IR: See website
<
Key People
Ian F. Smith
Executive Chairman of the Board
Alexander Cumbo
President, Chief Executive Officer, Director
Ilan Ganot
Co-Founder, Director
Kevin Tan
Chief Financial Officer, Treasurer
Paul Herzich
Chief Technology Officer
David Tyronne Howton
Chief Administrative Officer and Secretary
Gabriel Brooks
Chief Medical Officer
Jessie Hanrahan
Chief Regulatory Officer
Jennifer Marlowe
Chief Scientific Officer - Friedreich'��s Ataxia and Cardiac Pipeline
Business Overview
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Financial Overview
For the fiscal year ended 31 December 2023, Solid Biosciences Inc revenues decreased from $8.1M to $0K. Net loss increased 12% to $96M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Gain on acquisition decrease from $18.2M (income) to $0K, General and administrative increase of 20% to $23.2M (expense).
Employees: 88 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $227.69M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$101.36M as of Dec 31, 2023
Net annual income (TTM): -$96.02M as of Dec 31, 2023
Free cash flow (TTM): -$95.70M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 37,756,877 as of Mar 5, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.